Drug intelligence / Profile preview

MEDiC-03

Development stage: Preclinical
Lead developer: Medic Life Sciences
Modality: Small Molecules

Overview

MEDiC-03 is a preclinical-stage therapeutic candidate being developed by Medic Life Sciences. It is designed to target the Epidermal Growth Factor Receptor (EGFR) to address resistance mechanisms that arise following treatment with existing EGFR inhibitors in solid tumors. The program was identified using Medic Life Sciences' proprietary MCAT (Medic Cancer Analysis Tool) platform, which utilizes CRISPR-based functional genomics and 3D tumor models to discover novel targets and drug candidates for treatment-resistant cancers. As of 2024, the program is in the target discovery and preclinical validation phase.

Other names: MEDiC-03MEDiC03MEDiC 03

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on MEDiC-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDiC-03.

Explore the full profile